Synthesis and biological evaluation of benzothiazole derivatives as potent antitumor agents.
Based on 2-methyl-4-nitro-2H-pyrazole-3-carboxylic acid[2-(cyclohexanecarbonylamino)benzothiazol-6-yl]amide (1), which shows selective cytotoxicity against tumorigenic cell lines, 2,6-dichloro-N-[2-(cyclopropanecarbonylamino)benzothiazol-6-yl]benzamide (13b) was designed and synthesized as a biologically stable derivative containing no nitro group. The highly potent derivative 13b exhibited excellent in vivo inhibitory effect on tumor growth.
Yoshida
Masao
M
Medicinal Chemistry Research Laboratories, Sankyo Co. Ltd., Shinagawa-ku, Tokyo 140-8710, Japan.
Hayakawa
Ichiro
I
Hayashi
Noriyuki
N
Agatsuma
Toshinori
T
Oda
Youko
Y
Tanzawa
Fumie
F
Iwasaki
Shiho
S
Koyama
Kumiko
K
Furukawa
Hidehiko
H
Kurakata
Shinichi
S
Sugano
Yuichi
Y
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D052160:Benzothiazoles / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015195:Drug Design; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D051379:Mice; D015394:Molecular Structure; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D023041:Xenograft Model Antitumor Assays
C506243:2,6-dichloro-N-(2-(cyclopropanecarbonylamino)benzothiazol-6-yl)benzamide; D000970:Antineoplastic Agents; D001549:Benzamides; D052160:Benzothiazoles; D013844:Thiazoles; C005465:benzothiazole